Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older.
about
Influenza vaccines for preventing cardiovascular diseaseThe relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adultsSeasonal influenza vaccine policy, use and effectiveness in the tropics and subtropics - a systematic literature reviewInfluenza vaccination in the elderly: why are the overall benefits still hotly debated?Influenza and Memory T Cells: How to Awake the ForceReverse Genetics Approaches for the Development of Influenza VaccinesInfluenza A virus attenuation by codon deoptimization of the NS gene for vaccine developmentMucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbitsInfluenza Vaccination of Healthcare Workers: Critical Analysis of the Evidence for Patient Benefit Underpinning Policies of Enforcement.Adverse drug events monitoring of live attenuated pandemic influenza vaccine.Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trial.Mutations Designed by Ensemble Defect to Misfold Conserved RNA Structures of Influenza A Segments 7 and 8 Affect Splicing and Attenuate Viral Replication in Cell CulturePneumonia immunization in older adults: review of vaccine effectiveness and strategiesDevelopment of live-attenuated influenza vaccines against outbreaks of H5N1 influenza.Balancing the Efficacy and Safety of Vaccines in the Elderly.Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains.Rearrangement of Influenza Virus Spliced Segments for the Development of Live-Attenuated Vaccines.Vaccine effectiveness against laboratory-confirmed influenza hospitalizations among elderly adults during the 2010-2011 seasonInfluenza Vaccination for Secondary Prevention of Cardiovascular Events: A Systematic Review.Present and future of influenza prevention in pediatrics.Quadrivalent Ann Arbor strain live-attenuated influenza vaccine.Adjuvanted influenza vaccines.Temperature-Sensitive Live-Attenuated Canine Influenza Virus H3N8 VaccineDevelopment of Endotoxin Tolerance Does Not Influence the Response to a Challenge with the Mucosal Live-Attenuated Influenza Vaccine in Humans In Vivo.Influenza vaccines: Evaluation of the safety profile.Development of a novel equine influenza virus live-attenuated vaccine.Hintergrundpapier der STIKO: Evaluation der bestehenden Influenzaimpfempfehlung für Indikationsgruppen und für Senioren (Standardimpfung ab 60 Jahren).
P2860
Q24188037-909F09C5-13BB-4D00-9155-CED554E0EBE6Q24622008-4F2FEB72-38F7-4573-893D-3377D0FB13A7Q26769664-C9CAAC32-FD4F-47BA-889F-C6D4E2A55201Q26770659-9254A45D-C5CE-4D47-8C2C-623A742C9CF2Q28070255-9FBF80C7-2D3A-4631-8377-0C79096602CEQ28076140-F97903E1-CAC1-4DBF-98D1-3AA413592461Q28395006-6F07FA63-0B6F-435F-AF44-391DCD6055F1Q28476839-DCC6E892-BBC9-45DD-ACC0-DD2238E8D9FFQ30397977-26676A18-5444-4B82-935F-72CF65BE5877Q30409583-110FECA1-7724-4B2D-9462-B67677B51188Q34768241-D531A3A9-CA9C-454E-A5AE-F735E7810A2FQ36043803-69959226-2B1B-404E-993E-5D6E4008C027Q36393396-00A11121-E2CA-48F9-967B-DDCCFBE8FA92Q36482772-00C36330-9C2A-457B-9D48-39A2A51780D2Q36740019-AECC6A86-F8A7-4F6F-8B98-97D51F2A0D12Q36854011-C4DB5176-EF9F-41EA-A0FC-80D67F79463DQ37073339-D2070ED9-5C22-480D-A8E2-DE6397ED856FQ37111637-FA69BB25-400B-45D6-A803-27EE685231B7Q37711138-8E75F44E-9BAC-4BB1-95AB-5D18D0BB0C87Q37848838-2A57E477-C330-48FF-8BB7-B45E0FAEFBA1Q38059737-7378656E-53FE-43F7-9098-A937AE9231C9Q38140045-3363AE13-7BE5-4422-931E-9E3BCF0883FDQ38727207-1A231817-FAC5-43F0-AC47-CBBC38EA2392Q47556941-2BC49C1B-2536-4EA7-8875-0EE4B9D19DAFQ49345779-46DE9A74-EEDB-41CA-BF6D-F64F2D993E97Q50054245-166CB14E-0FBC-4D2F-BF4C-5EFD2C9CA96EQ52845428-5DA626D1-5E18-4666-A783-978D6BFB9F31
P2860
Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Efficacy and safety of a live ...... lts 60 years of age and older.
@en
type
label
Efficacy and safety of a live ...... lts 60 years of age and older.
@en
prefLabel
Efficacy and safety of a live ...... lts 60 years of age and older.
@en
P2093
P1433
P1476
Efficacy and safety of a live ...... lts 60 years of age and older.
@en
P2093
A Duncan Steele
Andrew J Dunning
Bruce D Forrest
LAIV Elderly Study Trial Network
Louis A Hiemstra
Pierre J T De Villiers
Ruth Rappaport
William C Gruber
P304
P356
10.1016/J.VACCINE.2009.09.092
P407
P577
2009-09-29T00:00:00Z